Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BPTF | Q12830 | 6/20 | 0.72 |
| ▸ | KAT2B | Q92831 | 15/20 | 0.60 |
| ▸ | BRD4 | O60885 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17916632 | 0.90 | BPTF (0.69) | BPTFKAT2BBRD4 | |
| SCHEMBL17916625 | 0.84 | BPTF (1.00) | BPTFKAT2B | |
| SCHEMBL17916705 | 0.80 | BPTF (0.70) | BPTFKAT2B | |
| SCHEMBL17916636 | 0.78 | KAT2B (0.60) | BPTFKAT2BBRD4 | |
| SCHEMBL17912389 | 0.77 | BPTF (0.93) | BPTFKAT2B | |
| Hydrochloric Acid SCHEMBL17912351 | 0.76 | BPTF (0.91) | BPTFKAT2B | |
| SCHEMBL17912365 | 0.76 | BPTF (1.00) | BPTFKAT2B | |
| SCHEMBL17916634 | 0.76 | BPTF (0.85) | BPTFKAT2B | |
| SCHEMBL17916727 | 0.75 | KAT2B (1.00) | BPTFKAT2B | |
| SCHEMBL17912352 | 0.75 | BPTF (0.98) | BPTFKAT2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10239861-B2 | Therapeutic compounds and uses thereof | GENETECH, INC. (US) | 2019-03-26 | — | — | US | disclosed |
| US-20180037566-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2018-02-08 | — | — | US | disclosed |
| US-20180037566-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2018-02-08 | — | — | US | disclosed |
| WO-2016112298-A1 | PYRIDAZINONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER | GENENTECH, INC. (US) | 2016-07-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10239861-B2 | Therapeutic compounds and uses thereof | HDAC10, HDAC6, HDAC11 | BPTF 20/4885KAT2B 103/4885BRD4 1320/4885 |
| US-20180037566-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | HDAC10, HDAC6, HDAC11 | BPTF 20/4885KAT2B 103/4885BRD4 1320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.